Seeking Alpha

ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design...

ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design clinical trial for its lead developmental drug, Gencaro, in atrial fibrillation. Medtronic (MDT) will be collaborating on the initial, phase 2B portion of the proposed trial.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|